



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49
Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2012

(Rs.in Lacs)

Particulars	3 Months Ended 30-Sept-2012 (Unaudited)	3 Months Ended 30-June-2012 (Unaudited)	Corresponding 3 months ended in the previous year 30-Sept-2011 (Unaudited)	Year To Date Figures For Current period ended 30-Sept-2012 (6 months) (Unaudited)	Year to date figure for the year ended 30-Sept-2011 (12 months) (Unaudited)	Previous Accounting year ended 31- March-2012 (18 months) (Audited)
1 Income from operations						
(a) Net Sales/Income from operations (Net of excise duty)	3,278.77	3,012.71	2,611.68	6291.48	11420.37	16185.21
(b) Other Operating Income	129.32	163.14	127.01	292.46	501.53	808.21
Total income from operations (net)	3,408.09	3,175.85	2738.69	6,583.94	11921.90	16,993.42
2 Expenses						
(a) Cost of Materials Consumed	1,115.66	927.89	1,294.66	2043.55	4564.75	6744.15
(b) Purchase of traded goods	696.49	659.26	534.61	1355.75	2944.28	3670.50
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	82.71	29.07	-99.68	111.78	-160.28	-194.96
(d) Employee benefits expense	298.94	298.83	305.07	597.77	1299.26	1967.02
(e) Depreciation and amortisation expense	127.64	123.54	146.26	251.18	572.11	864.90
(f) Other expenses	571.13	579.55	485.41	1150.68	2256.86	3301.88
Total expenses	2,892.57	2,618.14	2,666.33	5510.71	11476.98	16353.49
3 Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)	515.52	557.71	72.36	1073.23	444.92	639.93
4 Other Income	119.29	62.73	36.30	182.02	207.67	409.05
5 Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	634.81	620.44	108.66	1255.25	652.59	1048.98
6 Finance costs	481.45	487.09	515.16	968.54	1898.71	3035.87
7 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5+6)	153.36	133.35	-406.50	286.71	-1246.12	-1986.89
8 Exceptional Items (Net)						
a PROFIT ON SALE OF FIXED ASSETS						
b Foreign Currency Monetary Item Translation					-158.64	
c Amortization of Expenses for restructuring	-12.48	-12.49	-	-24.97	-	-12.49
d Excess provision written back	-	62.21	-	62.21	-	1246.71
8 Total Exceptional items (Net)	-12.48	49.72	-	37.24	-158.64	1234.22
(ii) Provision for Taxation of earlier years	-0.39	-	-	-0.39	-	-
9 Profit/(Loss) from Ordinary Activities before tax (7+8)	140.49	183.07	-406.50	323.56	-1404.76	-752.67
10 Tax Expenses	-	-	-	-	-	-
11 Net Profit/(Loss) from Ordinary activities after tax (9+10)	140.49	183.07	-406.50	323.56	-1404.76	-752.67
12 Extraordinary Item (net of tax expenses)	-	-	-	-	-	-
13 Net Profit/(Loss) for the period (11+12)	140.49	183.07	-406.50	323.56	-1404.76	-752.67
14 Share of Profit/(Loss) of associates	-	-	-	-	-	-
15 Minority interest	99.04	87.99	-115.68	187.04	-115.16	-63.01



Lyka Labs Limited



MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49

Website : lykalabs.com • Email : enquiry @ lykalabs.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED 30TH SEPTEMBER 2012

		(Rs.in Lacs)				
Particulars	3 Months Ended 30-Sept-2012	3 Months Ended 30-June-2012	Corresponding 3 months ended in the previous year 30-Sept-2011	Year To Date Figures For Current period ended 30-Sept-2012 (6 months)	Year to date figure for the year ended 30-Sept-2011 (12 months)	Previous Accounting year ended 31-March- 2012 (18 months)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
16 Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	41.45	95.08	-290.82	136.52	-1289.60	-689.66
17 Paid up equity share capital (face value Rs.10/- per share)	2158.00	2158.00	2158.00	2158.00	2158.00	2158.00
18 Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year	-	-	-	-	-	3,525.69
19 i. Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)						
(a) Basic	0.19	0.85	-1.88	0.60	-6.51	3.25
(b) Diluted	0.19	0.85	-1.88	0.60	-6.51	3.25
19 ii. Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)						
(a) Basic	0.19	0.85	-1.88	0.60	-6.51	3.25
(b) Diluted	0.19	0.85	-1.88	0.60	-6.51	3.25
A PARTICULARS OF SHAREHOLDING						
1 Public Shareholding						
- Number of shares	16552735	16552735	16979735	16552735	16979735	16552735
- Percentage of shareholding	76.70	76.70	78.68	76.70	78.68	76.70
2 Promoters and promoter group - Shareholding						
a. Pledged / Encumbered						
- Numbers of Shares	4965615	4965615	4208615	4965615	4208615	4965615
- Percentage of shares (as a % of the total shareholding of promoter and promoter group	98.77	98.77	91.49	98.77	91.49	98.77
- Percentage of shares (as a % of the total share capital of the company)	23.01	23.01	19.50	23.01	19.50	23.01
b. Non - encumbered						
- Number of shares	61650	61650	391,650	61650	391650	61650
- Percentage of shares (as a % of the total shareholding of promoter and promoter group	1.23	1.23	8.51	1.23	8.51	1.23
- Percentage of shares (as a % of the total share capital of the company)	0.29	0.29	1.82	0.29	1.82	0.29

PARTICULARS		3 Month ended
B INVESTOR COMPLAINTS		
Pending at the beginning of the quarter	-	
Received during the quarter	-	
Disposed of during the quarter	-	
Remaining unresolved at the end of the quarter	-	



Notes:

1. The above results were duly considered by the Audit Committee on 12th November, 2012, and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12th November, 2012.
2. Limited Review financial results for the quarter ended 30/09/2012 have been consolidated with that of Lyka BDR International Ltd., as approved by their Board.
3. During the quarter Company has charged Rs.19.14 lacs being depreciation on revalued assets.
4. During the Quarter, the Company has capitalised interest of Rs.15.29 lacs towards the Term Loan for Tarapur Upgradation and Rs.27.43 lacs towards pending allocation to Intangible Assets.
5. The Company's factory at Tarapur is under upgradation. In view of this, the production has been suspended.
6. The Company has one Single Segment "Pharmaceuticals".
7. Previous periods figures have been regrouped/rearranged wherever necessary.

For L YKA LABS LIMITED

(N. I. GANDHI)

Chairman & Managing Director

Mumbai
12-Nov-12.



Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti-Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49
Website : lykalabs.com • Email : enquiry @ lykalabs.com

Consolidated statement of Assets and Liabilities

Particulars		As at Current half year ended 30 Sept, 2012	As at Previous year ended 31 March, 2012
		Unaudited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' Funds		
	(a) Share Capital	2,266.57	2,266.57
	(b) Reserves and Surplus	5,171.98	5,121.22
	Sub-Total -Shareholders' Fund	7,438.55	7,387.79
2	Minority Interest	356.56	169.52
3	Non-Current Liabilities		
	(a) Long-Term Borrowings	6,035.09	5,112.26
	(b) Other Long-Term Liabilities	87.98	87.88
	(c) Long-Term Provisions	303.30	277.44
	Sub -Total -Non -Current liabilities	6,426.37	5,477.58
4	Current Liabilities		
	(a) Short-Term Borrowings	7,878.61	7,014.70
	(b) Trade Payables	3,692.24	4,507.45
	(c) Other Current Liabilities	3,428.91	3,620.58
	(d) Short-Term Provisions	82.96	75.14
	Sub -Total -Current liabilities	15,082.72	15,217.87
	TOTAL-EQUITY AND LIABILITIES	29,304.20	28,252.76
B	ASSETS		
1	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	12,326.60	12,666.63
	(ii) Capital Work-in-Progress	1,143.01	1,082.49
	(iii) Intangible assets under development	962.86	800.05
		14,432.47	14,549.17
	(b) Non-Current Investments	553.32	552.30
	(c) Long-Term Loans and Advances	1,274.95	1,348.31
	(d) Other Non Current Assets	253.30	-
	Sub -Total -Non-Current assets	16,514.04	16,449.78



Lyka Labs Limited

MANUFACTURERS OF PHARMACEUTICALS

Admn. Office : 101, Shiv Shakti Industrial Estate, Sir M. V. Road,
Andheri (E), Mumbai-400 059. • Phones : 6611 2200 • Fax : 6611 2248 / 49
Website : lykalabs.com • Email : enquiry @ lykalabs.com

Consolidated statement of Assets and Liabilities

Particulars		As at Current half year ended 30 Sept, 2012	As at Previous year ended 31 March, 2012
		Unaudited	Audited
2	Current Assets		
	(a) Current Investments	-	1.00
	(b) Inventories	1,458.89	1,607.83
	(c) Trade Receivables	7,432.08	6,102.79
	(d) Cash and Cash Equivalents	650.43	219.02
	(e) Short-Term Loans and Advances	2,499.34	3,182.32
	(f) Other Current Assets	749.42	690.02
	Sub -Total -Current assets	12,790.16	11,802.98
	TOTAL-ASSETS	29,304.20	28,252.76
<div style="text-align: right;">FOR LYKA LABS LIMITED  (N.I. Gandhi) (Chairman & Managing Director)</div>			